Peptides

Retatrutide Research Overview

Research overview of retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 clinical trial data and mechanism of action.

Retatrutide (LY3437943) is a novel investigational peptide that simultaneously activates three receptor systems: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple agonist approach represents a new frontier in incretin-based research, with Phase 2 clinical trial data generating considerable scientific interest. Retatrutide is being developed by Eli Lilly and Company.

Mechanism of Action

Triple Receptor Agonism

Retatrutide is engineered as a single peptide molecule that acts as an agonist at three distinct receptors:

GLP-1 Receptor Activation

  • Enhances glucose-dependent insulin secretion
  • Suppresses glucagon release
  • Slows gastric emptying
  • Modulates central appetite pathways

GIP Receptor Activation

  • Augments insulin secretion in a glucose-dependent manner
  • Researchers have observed that GIP receptor activation may enhance fat oxidation and energy expenditure
  • May counteract some of the nausea associated with GLP-1 receptor activation alone

Glucagon Receptor Activation

  • Increases hepatic glucose output and energy expenditure
  • Researchers have observed that glucagon receptor activation may promote lipolysis and fat oxidation
  • May contribute to reductions in liver fat content

Rationale for Triple Agonism

The theoretical basis for combining all three receptor targets builds on the established biology of incretin hormones:

  • GLP-1 receptor agonism provides glycaemic control and appetite suppression
  • GIP receptor activation may enhance metabolic flexibility and reduce GLP-1-related nausea
  • Glucagon receptor activation increases energy expenditure and may address hepatic steatosis

Researchers have hypothesised that this triple mechanism could produce additive or synergistic effects on body weight, glycaemic control, and metabolic health beyond what is achievable with single or dual agonism.

Phase 2 Clinical Trial Data

Obesity Trial (NCT04881706)

The Phase 2 obesity trial was a 48-week, randomised, double-blind, placebo-controlled study examining retatrutide in adults with obesity or overweight. Key findings:

  • Researchers observed dose-dependent reductions in body weight across all retatrutide groups
  • At the highest dose (12 mg weekly), participants experienced mean body weight reductions of approximately 24.2% at 48 weeks
  • A significant proportion of participants achieved greater than 15% body weight reduction
  • Improvements in glycaemic markers, blood pressure, and lipid profiles were also reported
  • The most common adverse events were gastrointestinal in nature (nausea, diarrhoea, constipation), consistent with GLP-1 receptor agonist class effects

These results were presented at the American Diabetes Association Scientific Sessions in 2023 and subsequently published in the New England Journal of Medicine (Jastreboff et al., 2023).

Type 2 Diabetes Trial

A separate Phase 2 trial examined retatrutide in participants with type 2 diabetes:

  • Researchers observed significant HbA1c reductions compared to placebo
  • Body weight reductions were also observed in the diabetes population
  • Glycaemic improvements appeared to be dose-dependent

Ongoing Research

Phase 3 clinical trials (the TRIUMPH programme) are underway to further evaluate retatrutide’s efficacy and safety profile in larger populations.

Australian Research Context

Clinical trials for retatrutide have been registered on ClinicalTrials.gov with sites in multiple countries, including Australia. Researchers interested in the Australian trial sites can search ClinicalTrials.gov using the trial identifiers for the Phase 3 programme.

Retatrutide is not approved by the TGA and is not listed on the Australian Register of Therapeutic Goods (ARTG). As an investigational compound, it is not available as an approved medicine in Australia. The TGA evaluates new medicines based on submitted clinical data, and any future approval would depend on the outcomes of the Phase 3 programme and regulatory submissions.

Why Retatrutide Is Generating Research Interest

Several factors contribute to the scientific interest in retatrutide:

  • Unprecedented weight reduction: The Phase 2 data reported body weight reductions exceeding those observed with dual GLP-1/GIP agonism (tirzepatide) at comparable timepoints
  • Triple mechanism novelty: The addition of glucagon receptor activation to the incretin agonist framework represents a pharmacological first
  • Metabolic breadth: Researchers have observed improvements across multiple metabolic parameters simultaneously
  • Hepatic effects: Glucagon receptor activation may offer specific benefits for fatty liver conditions
  • Energy expenditure: Unlike pure GLP-1 agonists that primarily reduce intake, retatrutide’s glucagon component may also increase expenditure

Research Limitations

As with all investigational compounds, important caveats apply:

  • Phase 2 data, while promising, requires confirmation in larger Phase 3 trials
  • Long-term safety data beyond 48 weeks is not yet available
  • The full risk-benefit profile is still being characterised
  • Individual responses may vary significantly
  • Preclinical findings from receptor pharmacology do not always predict clinical outcomes
  • GLP-1 Peptides - Comprehensive overview of GLP-1 receptor agonist research including semaglutide and tirzepatide
  • MOTS-c - A mitochondrial-derived peptide studied in metabolic research
  • Tesamorelin - A GHRH analogue studied in body composition research

For research literacy and educational purposes only. This content does not constitute medical advice or therapeutic recommendation. Consult a qualified healthcare professional for medical decisions.